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Abstract: CT1812 is an orally bioavailable, brain penetrant small molecule antagonist of the 
sigma-2 receptor complex with a novel disease-modifying mechanism of action against 
Alzheimer’s disease (AD). Amyloid beta (Aβ) oligomers are one of the most toxic structural 
forms of the Aβ protein and are hypothesized to cause synaptotoxicity and memory failure as 
they build up in Alzheimer’s patients’ brain tissue. CT1812 displaced Aβ oligomers bound to 
synaptic receptors in three independent preclinical models of AD, facilitated oligomer clearance 
into the CSF, increased synaptic number and protein expression in neurons, and improved 
cognitive performance in transgenic mice. In a phase 1b/2a clinical trial, CT1812 increased CSF 
concentrations of Aβ oligomers, reduced concentrations of synaptic proteins and phosphorylated 
tau fragments, and reversed expression of many of the AD-related proteins dysregulated in CSF 
when administered to mild to moderate AD patients once daily for 28 days. These results are 
consistent with preclinical data and provide evidence of target engagement and impact on 





Alzheimer’s disease (AD) afflicts six million people in the US, yet disease modifying therapies 
remain an unmet medical need. Investigational therapeutics are directed against a variety of 
potential targets [1] but the amyloid hypothesis remains a compelling rationale for AD drug 
development [2]. More than 200 human mutations that cause early-onset familial AD have been 
identified, almost all conferring a single phenotype, increased Aβ protein concentration or ratio 
[3,4]. The only protective mutation that both significantly lowers AD incidence and also exhibits 
strong functional evidence of protection, A673T (the Icelandic mutation), also impacts the Aβ 
protein [5] resulting in significantly lowered binding affinity of Aβ oligomers at synaptic 
receptors [6]. Previous therapeutics have not effectively targeted amyloid beta (Aβ) oligomers 
[7], one of the most toxic structural forms of the Aβ protein [8]. While monomeric Aβ binds to 
many receptors, the oligomeric form of Aβ has been shown to bind specifically and saturably to 
a single receptor site composed of LilRB2, Nogo receptor, and cellular prion proteins [9–11] on 
neuronal synapses, where they induce changes consistent with a toxic disease-related ligand. 
Following oligomer binding, synaptic protein expression and the number of spines and synapses 
are reduced [12–16],  synaptic plasticity processes (long term potential and depression) are 
disrupted [14,17–25] and the process of new memory formation fails [2,8,10,11,26]. Importantly, 
many preclinical studies suggest that following removal or reduction of the toxic oligomer 
species, synaptic protein expression, synapse number, and behavioral deficits can recover to 
normal levels [12,27].  
Here we report the discovery and continued development of drug candidate CT1812, a brain 
penetrant small molecule that targets Aβ oligomers via a novel mechanism [26,28]. The first 
selective sigma-2 receptor antagonist to reach clinical trials [29], CT1812 is shown here to 
specifically displace Aβ oligomers bound to neuronal receptors at synapses without affecting 
monomer concentration. The sigma-2 receptor complex plays a major role in cellular damage 
response mechanisms, with its constituent proteins regulating processes as diverse as autophagy, 
cholesterol synthesis and progesterone signaling, lipid membrane-bound protein trafficking and 
receptor stabilization at the cell surface [30–37]. The sigma-2 receptor complex has been 
previously shown to be a key regulator of Aβ oligomer receptors [26,28]. In the present study, 
we demonstrate that when CT1812 binds specifically to the sigma-2 receptor ligand binding site 
and allosterically modulates the sigma-2 receptor complex, it causes destabilization of the 
neighboring Aβ oligomer receptor binding sites, resulting in displacement of Aβ oligomers from 
their receptors (in other words, an increase in their “off rate”). This lowers Aβ oligomer affinity 
for synaptic receptors, which phenocopies the effect of the protective Icelandic mutation. This 
disruption of oligomer binding has previously been associated with an improvement in 
membrane trafficking, neuronal surface expression of synaptic proteins, prevention of spine loss, 
and improvement in cognitive deficits in animal models of AD [26,28].  
The present study additionally reports preclinical data demonstrating the novel mechanism of 
action of CT1812 in vitro and in vivo in an AD transgenic mouse model that highlights its 
potential therapeutic value and preliminary CSF biomarker data from the completed phase 1b/2a 
trial (NCT02907567), supporting its disease-modifying mechanism in AD patients [29].  
Results  
CT1812 displaces and prevents A oligomer binding 
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Previously published studies that described unbiased proprietary library screening to identify 
compounds that block Aβ oligomer-induced toxicity of intracellular lipid membrane trafficking 
rates revealed compound potency correlated with sigma-2 receptor affinity [26,28]. Medicinal 
chemistry optimization resulted in the design of CT1812. CT1812 binds sigma-2 receptors with 
high affinity (Fig. 1A, Ki = 8.5 nM), sigma-1 receptors with low affinity (Ki = 63 nM), and is 
100-fold selective for interacting with sigma-2 receptors vs. 72 other drug targets 
(Cerep/Eurofins Supplementary Fig. S1). CT1812 effectively prevented (EC50 = 6.7 M) and 
reversed (EC50 = 0.36 M) synthetic Aβ oligomer-induced membrane trafficking deficits in 
vitro in primary hippocampal/cortical cultures (21DIV, Fig. 1B) and prevented human AD 
patient brain-derived oligomer-induced trafficking deficits (Fig 1C). CT1812 prevented binding 
of A oligomers to synaptic receptor sites on neurons (Aβ oligomer binding Kd = 0.43 μM, plus 
CT1812 = 1.12 μM, Fig. 2A, B, D), and also displaced already-bound Aβ oligomers (Aβ 
oligomer binding Kd = 0.61 μM, plus CT1812 = 1.16 μM, Fig. 2C, E). CT1812 did not block the 
formation of Aβ oligomers or disrupt their formation at concentrations up to 20µM 
(Supplementary Fig. S2), suggesting that its ability to stop Aβ oligomer binding and trafficking 
deficits results from CT1812 direct binding to sigma-2 receptors.  
CT1812 restores disease-related protein expression and synapse number in vitro  
Aβ oligomers induce reversible spine retraction in vitro [38] and cause a corresponding loss of 
synapses and synaptic proteins [13,26]. The effect of CT1812-induced displacement of Aβ 
oligomers on oligomer-induced spine and synapse loss in cultured rat neurons was investigated 
using the cytoskeleton binding protein drebrin (expressed postsynaptically) as a marker of 
synapse number. Addition of Aβ oligomers to neuronal cultures for 3 hours caused a significant 
loss (mean ± SEM 12.8% ± 2.6%, p < 0.01, 2-tailed Students t-test, Fig. 2F top, G) of drebrin-
immunoreactive synaptic puncta per neuron compared to vehicle treatment. This is similar to the 
degree of synapse loss seen using ultrastructural stereology methods in postmortem hippocampus 
from humans diagnosed with mild cognitive impairment [39]. CT1812 prevented oligomer-
induced synapse loss in a dose-dependent manner (EC50 = 68 nM, p < 0.05, paired, Student’s t-
test of treated vs. vehicle, Fig. 2F bottom, G). Furthermore, addition of CT1812 to cultures 1 
hour after the addition of Aβ oligomers resulted in a concentration-dependent increase of 
synaptic number to normal levels (EC50 = 127 nM, Fig. 2G). Examination of synaptic protein 
expression corroborated these results. Neurogranin is expressed in dendrites and postsynaptic 
terminals (Fig. 2H), while synaptotagmin-1 is expressed in presynaptic terminals (Fig. 2K) of 
mature primary hippocampal/cortical neurons in vitro. A oligomer treatment led to a 28% loss 
of neurons expressing high levels of neurogranin (Fig. 2I) and a 37% loss of synaptotagmin-1 
presynaptic terminals (Fig. 2L). Treatment with CT1812 blocked this loss and restored 
expression of both proteins to control levels (Fig. 2J, M). This suggests that CT1812-mediated 
displacement of A oligomers from neuronal synapses stops both downstream oligomer-induced 
synaptic protein downregulation and synapse loss, facilitating synaptic recovery from toxic 
oligomer insult. 
CT1812 displaces A oligomers and facilitates clearance into CSF in vivo and in AD patient 
brain tissue 
To confirm the displacement of A oligomers from cells observed in vitro using an in vivo 
mouse model of AD, we adapted a novel microimmunoelectrode (MIE) technology previously 
used to detect rapid kinetic changes in total Aβ concentration in brain interstitial fluid (ISF) [40] 
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(Supplementary Fig. S3A-E). Using electrodes coated with the oligomer specific antibody A11 
[41] placed in the hippocampus, Aβ oligomers were measured in ISF of 12 month old 
APPSwe/PS1dE9 transgenic mice [42]. A single dose of CT1812 (0.3 µM, or 3.0 µM i.v.) resulted 
in a rapid and significant increase in Aβ oligomer levels in hippocampal ISF relative to predose 
baseline (Fig. 3A, vertical dashed line, see Supplementary Fig. S3F). In contrast, no increase was 
observed in the ISF of vehicle-treated transgenic mice. The rapid elevation of Aβ oligomers after 
drug administration declined to baseline levels within the timeframe of the recording (120 
minutes). In contrast, total Aβ levels (primarily monomer) in the hippocampal ISF were not 
affected by the administration of CT1812 (Fig. 3B), thus CT1812 selectively reduces Aβ 
oligomer extracellular concentrations without affecting Aβ monomer levels. 
To assess whether CT1812 displacement of Aβ oligomers in AD model systems in vitro and in 
vivo may also occur in AD patients, we conducted ex vivo binding experiments in 10 M-thick 
postmortem neocortical tissue sections obtained from patients with AD (Clinical Dementia 
Rating (CDR)=3, n=8 patients, Fig. 3C-E). Following incubation of adjacent sections in identical 
volumes containing increasing concentrations of CT1812 or vehicle, the supernate was removed 
and the levels of A displaced from the tissue sections quantified by ELISA; the A remaining 
in the tissue sections was quantified via immunofluorescent microscopy. Analysis of the 
displaced material by ELISA for total Aβ showed that ascending concentrations of CT1812 
increased the amount of Aβ released from the human brain tissue (Fig. 3D): non-denaturing 
western blots confirmed this material to be Aβ oligomers (Fig. 3C, E, Supplementary Fig. S4). 
Additionally, CT1812 induced a concentration-dependent decrease in Aβ oligomer 
immunofluorescence intensity in the 2 m region containing high concentrations of oligomers 
surrounding dense, thioflavin-S labeled plaque cores [43,44] (Fig. 3F, G) with similar but not 
statistically significant changes occurring within the plaque itself (Fig. 3H). These results 
demonstrate that CT1812 displaces prebound Aβ oligomers from AD patient brain tissue.  
Finally, the fate of Aβ oligomers displaced by CT1812 was determined by placing the A11-
coated MIE in the lateral ventricle of transgenic APPSwe/PS1dE9 mice to measure Aβ oligomers 
in the CSF. A significant, dose-dependent rise in Aβ oligomer levels was detected in CSF after 
drug administration (Fig. 3I) and remained elevated for up to two hours, suggesting that 
displacement of A oligomers in the brain may lead to increased clearance into the CSF. In 
contrast, Aβ monomer levels in the CSF were not affected by administration of CT1812 (Fig. 
3J), indicating that CT1812 selectively facilitates clearance of oligomers, but not monomers, 
from the brain into the CSF. 
CT1812 improves cognitive performance in transgenic mice 
To assess whether this evidence of synapse preservation by CT1812 was associated with 
functional behavioral improvement, we evaluated changes in cognitive deficits in an aged 
transgenic mouse model of AD [26,45,46]. Transgenic Thy1 huAPPSwe/Lnd+ male mice, aged 3.5 
to 4.5 months, or wild-type (WT) littermates were administered vehicle or CT1812 10 mg/kg 
once daily by oral gavage for 9-10 weeks (n=12 for each group except for the transgenic 
CT1812-treated group, which was n=13). Treatment of WT mice with CT1812 did not 
significantly alter motor behavior and did not change cognitive performance compared to that of 
WT vehicle-treated animals. As expected, significant deficits in transgenic vehicle-treated 
animals compared to WT vehicle-treated animals were observed in the Activity Chamber test 
measuring exploration, the Y maze measuring spatial working memory, and the Fear 
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Conditioning assays measuring aversive associative learning and memory. Significant 
improvements in spatial learning and memory were observed in animals treated with CT1812 
compared to those treated with vehicle in the Water Maze (Fig. 4A), the Y-Maze (Fig. 4B), and 
in contextual fear conditioning (Fig. 4C). In addition to improving spatial learning and memory, 
significant improvements were observed in hyperactivity as assessed via the Activity Chamber 
assay, and cue-dependent learning and memory, as assessed in the Fear Conditioning assay. In 
wild-type mice, CT1812 had no effect on performance in any of the cognitive tests (Fig. 4A-C). 
Previously published studies of eight other sigma-2 receptor antagonists closely related to 
CT1812 in Thy1 huAPPSwe/Lnd+ mice treated daily for 4 weeks-6 months indicated that 
behavioral improvements were observed as long as brain concentrations of drug were above a 
theoretical 80% receptor occupancy threshold concentration [26], but that plaque number and Aβ 
monomer concentration (measured by ELISA) did not change. PK measurements of brain 
concentrations of CT1812 following treatment of Thy1 huAPPSwe/Lnd+ mice with 10 mg/kg p.o. 
for 9-10 weeks confirmed that this estimated 80% receptor occupancy level was achieved (Fig. 
4D, brain concentration 24 hours after last dose = 19.9 ng/mL, 84.4% receptor occupancy, 
greater than four times the sigma-2 receptor Ki value). Taken together, these studies indicate that 
threshold brain concentrations of CT1812 effectively improved cognitive deficits found in the 
huAPPSwe/Lnd+ mouse model of AD. 
Clinical biomarker evidence of CT1812-mediated synapse protection and disease modification 
Following completion of first-in-man clinical studies (NCT02570997 [29]), CT1812 was 
advanced into clinical trials in AD patients. Mild-to-moderate AD patients with Mini Mental 
State Exam (MMSE) scores of 18-26 were randomized to receive one of three doses of CT1812 
(90 mg, 280 mg, 560 mg) or placebo once daily for 28 days (N=19, 4-5/group) in a double-blind 
phase 1b/2a clinical trial to determine safety and tolerability (trial COG0102, for full description, 
see clinicaltrials.gov NCT02907567). The randomized patients, 10 male and 9 female, had a 
mean age of 70.2 years (SD 9.2) and BMI of 24.75 kg/m2 (SD 2.73). CSF concentrations at 
baseline and Day 28 confirmed no presence of CT1812 in the placebo group or at baseline in any 
dose group. Day 28 mean CSF concentrations of CT1812 rose in a dose-dependent manner (1.15 
ng/mL (SD 0.53) in the 90 mg treatment group, 2.84 ng/mL (SD 0.69) in the 280 mg treatment 
group, and 4.96 (SD 8.49) in the 560 mg treatment group. As expected in a study of limited 
treatment duration, change in exploratory measures of cognitive function from baseline was 
similar in CT1812-treated and placebo groups. CSF samples collected from each patient at 
baseline and at the end of study were used for protein measurements using targeted (i.e., ELISA, 
western blot, LC-MS/MS) and non-targeted (i.e., unbiased LC-MS/MS proteomics) methods; 
missing samples and variable sample volumes reduced the number of matched baseline and day 
28 patient CSF samples available for subsequent analysis.   
Protein gel electrophoresis (western blot) was used to measure Aβ oligomer concentration in 
CSF samples from each patient taken at Day 0 and 28 and percent change for each patient was 
calculated. Due to the small number of AD patients in each dosing group, CT1812 dose groups 
were pooled for comparisons to placebo. After 28 days of treatment, CSF Aβ oligomer 
concentration (n = 3) in placebo-treated patients trended lower from levels at their own baseline, 
while levels in CT1812-treated patients (n = 10) increased significantly compared to placebo-
treated patients (Fig. 5A and Supplementary Fig. S5). This finding is consistent with preclinical 
studies indicating that CT1812 displaces and clears toxic Aβ oligomers from the brain into CSF 
(Fig. 3I) and provides supporting evidence of clinical target engagement. In contrast, Aβ 40 and 
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42 monomer levels measured with ELISA were not different between Day 0 and Day 28, or 
between treatment groups in this trial (Supplementary Fig. S5C, D).  
The concentrations of several synaptic and axonal proteins are elevated in CSF of AD patients 
compared to age-matched cognitively normal individuals as a result of CNS synaptic damage 
due to the disease [47–51]; some markers exhibit greater sensitivity to disease-related changes 
than do others. We measured concentrations of synaptic and axonal proteins in CSF samples 
from AD patients in trial COG0102 using ELISA [neurogranin and neurofilament light (NfL)] or 
targeted LC-MS/MS (synaptotagmin-1, SNAP-25). At 28 days, CSF concentrations of 
neurogranin and SYT-1 decreased in CT1812-treated AD patients relative to placebo-treated AD 
patients CSF (Fig. 5B, neurogranin, n = 5 placebo, 11 treated; p=0.050 ANCOVA; Fig 5C, 
synaptotagmin-1, n = 4 placebo, 9 treated; F1,12 = 8.8, p = 0.011, linear mixed model), 
consistent with preclinical evidence of CT1812-mediated facilitation of synaptic recovery from 
insult with toxic Aβ oligomers. CSF concentrations of NfL and SNAP-25 did not change to a 
significant degree in CT1812-treated AD patients vs. placebo (Supplementary Fig. S5D, F).   
Data from unbiased LC-MS/MS proteomics measurements of CSF were evaluated for effects on 
synaptic proteins (Fig. 5D). Of the 3160 proteins detected in the CSF of this patient cohort, the 
abundance of 315 proteins was significantly different between CT1812- and placebo-treated 
patients (ANOVA followed by Fisher's Least Significant Difference (LSD); p<0.05). Pathway 
analysis using three independent bioinformatics platforms (IPA Canonical Pathway 
[v51963813], Metacore [v19.4 build 69900], STRING [v11]) indicates that CT1812 significantly 
(p<0.05) impacts synaptic-related pathways including N-methyl-D-aspartate receptor trafficking, 
glycogen kinase synthase kinase-3β (GSK3β) and WNT signaling, as well as cytoskeletal 
reorganization. Given the loss of synapses in AD patients along with the preclinical evidence that 
CT1812 rescues synapse number, we queried which proteins in the synaptic proteome [52] were 
altered by CT1812 treatment. Twenty five proteins in the synaptic proteome [52] were identified 
to be differentially expressed (ANOVA followed by Fisher's LSD; p<0.05) in CT1812- 
compared to placebo-treated patient CSF. To understand the functions of these proteins with 
respect to specific synaptic function in more detail, network analysis was performed. The highest 
scoring network, Cell Morphology, Cellular Assembly and Organization, Cellular Development, 
comprised 14 out of 25 of the synaptic proteins, a significantly greater number than expected by 
random chance (Supplementary Fig. S6A, IPA Score=26; p<1x10-25). This indicates that these 
proteins may play a role in dendritic branching, cytoskeletal remodeling, and neurotransmission 
(Supplementary Fig. S6B). This provides evidence supporting CT1812’s positive effect on 
synapses in patients with AD. 
Out of 520 CSF proteins significantly altered in AD patients vs. age-matched controls (p<0.05) 
in a recent study [53], 334 were detected in the COG0102 CSF proteomics dataset. Of those 334 
proteins, a subset of 20 moved in the opposite direction (i.e., reversed AD-related changes) and 
were also significantly different in CT1812-treated compared to placebo (Fig. 5E). Several of 
these proteins are involved in key biological pathways known to be disrupted in AD, including 
cholesterol transport (apolipoprotein A2; APOA2), oxidative stress (ceruloplasmin; CP), 
complement (complement C1r subcomponent-like protein; C1RL), and synaptic transmission 
(14-3-3 protein beta/alpha; YWHAZ). This provides supporting evidence for a broad 
improvement of disease-related signaling by CT1812 in patients with AD.  
One of the hallmarks of AD is hyperphosphorylated tau protein, which comprises neurofibrillary 
tangles (NFTs) [54–58]. We evaluated AD patient CSF for concentrations of unphosphorylated 
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and phosphorylated tau protein fragments taken at baseline and after 28 days of CT1812 or 
placebo treatment via LC-MS/MS (Fig. 5F); phosphorylated peptide fragments representing 33 
distinct phosphorylation sites on tau were detected. The abundance of 6 phosphorylation sites 
decreased by 30% or more (Fig. 5F) [59,60] after treatment with CT1812 compared to placebo 
while one site increased more than 30% (the threshold for noise distribution [61]), but the 
concentration of unphosphorylated tau did not change. In agreement with these results, ELISA 
measurements of the change from baseline of phospho tau (P-tau) (181) and total tau (T-tau) was 
similar in CT1812-treated and placebo groups (Supplementary Fig. S5E, F). Additionally, LC-
MS/MS measurements of concentrations of kinases that phosphorylate tau, such as GSK3β 
trended lower by 25% in CT1812-treated patients (not significantly different from placebo-
treated patients, p=0.098). These results suggest that CT1812 may act upstream of tau kinases to 
reduce their concentration and resulting activity, while having no impact on tau expression or 
regulation. In order to identify phosphorylation sites within tau that might covary in abundance 
in response to CT1812 treatment, correlation analyses were performed and a heatmap was 
generated. The abundance of 21 pairs of P-tau sites was found to be significantly correlated with 
one another (Supplementary Fig. S7), supporting the hypothesis that CT1812 may act upstream 
of tau kinases/phosphatase to impact tau phosphorylation at specific amino acid sites. Taken 
together, these clinical biomarker data support a potential therapeutic impact of CT1812 in 
patients with AD. 
Discussion  
CT1812 displaces A oligomers in several preclinical models of AD 
The Aβ oligomer hypothesis remains a compelling rationale for AD drug development programs 
[2]. Supporting evidence for this comes from the genetic determinants of autosomal dominant 
AD and AD complicating Down syndrome [62], the protective effect of the Icelandic mutation of 
the amyloid precursor protein [5,6] animal data indicating the toxic effects of Aβ oligomer 
species on synaptic function [8,63] and its reversibility [27], and the observation that Aβ 
accumulation alone in cognitively and clinically normal individuals predicts symptomatic AD 
with high likelihood [64]. Drug development programs targeting Aβ include active and passive 
Aβ immunotherapeutics [7] and secretase inhibitors that decrease Aβ peptide generation [65], but 
none effectively or selectively target Aβ oligomers.  
The current study demonstrates that CT1812 displaces Aβ oligomers from neurons with 3 
independent approaches: in vitro cell culture, in vivo rodent studies (including two different 
mouse models of AD), and ex vivo human brain CSF and tissue. In cultured rat brain cells in 
vitro, CT1812 shifted the binding of exogenously applied, synthetic Aβ oligomers to lower 
affinity whether added before or after oligomers. Importantly, CT1812-mediated reduction of 
oligomer affinity phenocopies or mimics the effect of the Alzheimer’s protective Icelandic 
mutation on oligomer affinity [66], and is the only drug candidate currently in development 
reported to do so. This is significant because drug candidates with the same mechanism as 
protective variants are expected to have a higher success rate in the clinic [67]. CT1812 
treatment for 1 hour did not decrease the intensity of pre-bound Aβ oligomers as completely as it 
did when added to cultures prior to the oligomers. It is possible that longer treatment with 
CT1812 can achieve a greater level of displacement. However, incubation with Aβ oligomers for 
longer times results in internalization of a portion of the Aβ oligomer labeling [26], complicating 
quantification of the compound treatment. Nonetheless, our results demonstrate that CT1812 
both displaces already-bound Aβ oligomers and prevents the binding of Aβ oligomers to 
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neuronal synaptic receptors; displaced oligomers will not re-bind as long as CT1812 remains 
present. Thus, CT1812 will likely continue to exert its effect as concentrations of oligomers rise 
throughout the course of AD. In separate biochemical assays using an oligomer-specific ELISA, 
CT1812 does not interact directly with oligomers and did not disrupt preformed oligomers or 
block oligomer formation (Supplemental Fig. S2). In postmortem human AD brain tissue 
sections, CT1812 caused a concentration-dependent increase in Aβ displaced from the tissue as 
measured by Aβ ELISA, as well as a concentration-dependent increase in several oligomeric 
species of Aβ as detected by western blot analysis of the material displaced from the tissue [68]. 
This was accompanied by a decrease in Aβ within the tissue section in the 2 micron oligomer-
enriched halo surrounding plaques. While we cannot rule out compound-mediated displacement 
of oligomers from extrasynaptic sites that are below the level of detection of our imaging 
methods, oligomers that are dose-dependently displaced by CT1812 are highly likely to originate 
from synaptic receptor sites; because oligomers are water-soluble, oligomers in the interstitial 
fluid in these frozen tissue sections should freely diffuse in any aqueous media and be detectable 
in the vehicle treated condition as well (Fig 3C-E). The transgenic mouse MIE measurements 
provide additional insight on the selectivity of CT1812’s effect on oligomers: a single dose of 
CT1812 rapidly increased concentrations of Aβ oligomer, but not Aβ monomer in brain. 
Together, these results demonstrate that CT1812 is a dose-dependent, negative allosteric 
modulator of Aβ oligomer binding. 
Unexpectedly, these same measurements provided evidence suggesting that CT1812 directly or 
indirectly facilitates clearance of Aβ oligomer, but not monomer, out of the brain and into the 
CSF; it rapidly increases ISF and CSF concentrations of oligomers in a dose-dependent manner, 
but not monomers. The difference in kinetic rate of increase in Aβ oligomer concentration 
between the hippocampus and lateral ventricle may result from different electrode sampling 
volumes due to diffusion constraints within brain tissue compared to CSF. The basis for this 
selective clearance of Aβ oligomers but not monomers is currently unclear. While mechanisms 
of Aβ monomer clearance from the brain into CSF have been studied extensively (reviewed in 
[40]), oligomer clearance mechanisms are currently unknown. One possible mechanism is 
suggested by recent studies demonstrating direct interactions of sigma-2 receptor complex 
component proteins PGRMC1 and TMEM97 with LDL receptor, required for ligand-bound LDL 
receptor internalization [31], and sigma-2 receptor-mediated cellular uptake of A via 
interactions with apolipoproteins and the LDL receptor [31,69]. Previously tested closely related 
sigma-2 receptor antagonists do not impact monomer or fibril levels in Thy1 huAPPSwe/Lnd+ 
transgenic mice following chronic short term administration [26]. To more fully explore the role 
of these proteins in AD, future studies (including studies in AD mouse models cross-bred with 
conditional tissue-specific knockouts of each protein to avoid lethality) are required. 
We hypothesize that displacement of toxic Aβ oligomers from synaptic receptor sites and 
clearance of oligomer into the CSF underlies the improvement of cognitive performance in 
transgenic AD mice seen with chronic CT1812 administration. As with other closely related 
sigma-2 receptor antagonists [26], CT1812 improves transgenic mouse behavior at brain 
concentrations corresponding to an estimated 80% receptor occupancy; typical for an antagonist 
mechanism of action, threshold concentrations of drug are required to block effects. While 
CT1812’s in vitro assay EC50 values range from high nanomolar to low micromolar 
concentrations, behavioral improvement is observed at brain concentrations closer to CT1812’s 
Ki at sigma-2 receptors (8.5 nM). The basis for this difference is unclear but may be due to the 
short duration and high concentrations of synthetic Aβ oligomers used in the in vitro assays. 
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Once displaced from synaptic receptors, the oligomers are no longer able to harm synapses and 
are subject to elimination through yet to be defined clearance pathways.  
Preliminary biomarker evidence for CT1812 target engagement and disease-modification in 
patients with AD 
Protein measurements of CSF samples from the 28-day clinical trial COG0102 provide 
preliminary evidence of target engagement and potential impact on disease in mild-to-moderate 
AD patients consistent with preclinical data. CSF concentrations of Aβ oligomers increase in 
CT1812-treated patients vs. placebo similar to preclinical studies, indicating that CT1812 
displaces and clears toxic Aβ oligomer from the brain into CSF. CSF concentrations of the 
postsynaptic dendritic protein neurogranin, typically significantly elevated in AD patients 
[51,70–72] are reduced by CT1812 treatment, compared with changes in placebo patients. 
Additionally, several synaptic proteins are significantly different in CT1812- vs. placebo-treated 
patients; bioinformatics analysis of these changes support preclinical evidence of a positive 
impact of CT1812 on synaptic pathways.  
Analysis of CSF concentrations of phosphorylated tau fragments in AD patients revealed that 
treatment with CT1812 induced a broad reduction in tau phosphorylation at multiple amino acid 
sites without affecting unphosphorylated tau concentration. Many of the residues altered by 
CT1812 treatment have been previously implicated in AD-related changes [73–78]. Data 
correlating phosphorylation at any given amino acid of tau with disease progression in patients 
(as well as how closely mouse disease models reflect such changes) are still emerging. 
Preclinical evidence demonstrates that Aβ oligomer binding results in upregulation of tau kinase 
activity [2] leading to tau phosphorylation at multiple sites. The observed reduction in GSK3β as 
well as tau phosphorylation in CT1812-treated patients provides the first clinical biomarker 
evidence supporting the Aβ oligomer hypothesis of AD and further support of CT1812’s disease-
modifying mechanism of action.  
We hypothesize that changes in CSF concentration of a subset of proteins with CT1812 
treatment reflect target engagement in the brain. Further clinical studies with longer treatment 
duration are underway; treatment-related impact on biomarkers in these independent clinical 
cohorts will provide additional insight on CT1812 target engagement and AD pathobiology as 
well as insight into how covariates like sex, age, and ApoE status impact response to drug. The 
effects of these changes in CSF protein concentrations on cognition and health is unknown and 
the relative benefit of these effects compared to the risks of the drug are being determined in 
ongoing and future placebo-controlled clinical trials.  
CT1812 for the treatment of AD 
The hypothesized disease-modifying mechanism of action of CT1812 is illustrated in Figure 6. 
In the normal brain (Fig. 6A), the sigma-2 receptor complex regulates the plasma membrane 
surface expression of putative Aβ oligomer receptor complex component proteins LilRB2, Nogo 
and cellular prion protein as well as several other receptors [79] (Fig. 6B). In AD, Aβ oligomers 
bind to their receptor, altering its function and/or protein interactions, and resulting in a 
compensatory upregulation of the sigma-2 receptor complex (Fig. 6C) [80,81]. The binding of 
A oligomers then leads to synaptic damage and release of presynaptic and postsynaptic proteins 
such as neurogranin and synaptotagmin-1 into the ISF and CSF (Fig. 6D). CT1812 binds to and 
allosterically modulates the sigma-2 receptor (Fig. 6E), causing destabilization of the 
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neighboring Aβ oligomer receptor binding sites with resultant displacement of Aβ oligomers 
from synaptic receptors (i.e., increase in the “off rate”) without affecting normal synaptic protein 
function. CT1812 is thus a negative allosteric modulator of Aβ oligomer binding to synaptic 
receptors. As a result of the removal of toxic oligomers, synapse number and memory are 
restored to normal (Fig. 6F). CT1812 selectively displaces Aβ oligomers shortly after entering 
the brain and prevents them from rebinding as long as brain drug levels remain above an 
estimated 80% receptor occupancy [26]. Chronic administration provides sustained protection 
from the synaptotoxic oligomer assault, facilitating synaptic recovery.  
The current studies suggest that CT1812 effectively and selectively targets Aβ oligomers by a 
novel mechanism of action not previously demonstrated for any other therapeutics currently in 
development. CT1812 is both the first selective sigma-2 receptor antagonist to be used in clinical 
trials, and the first therapeutic demonstrated to displace toxic Aβ oligomers from synaptic 
receptor sites and selectively facilitate their clearance into the CSF. Displacement of oligomers 
lowers their binding affinity (KD) to synaptic receptors significantly, thus CT1812 is the only 
therapeutic currently in development that mimics the effect of the protective Icelandic A673T 
mutation [6]. This mechanism is significant, as therapeutics that recapitulate the effects of 
protective mutations have a track record of clinical success [67]. 
Currently approved AD medications do not stop the disease course, but simply treat symptoms 
for a limited time. These preclinical results of CT1812 in rodent models of AD demonstrate that 
CT1812 blocks A oligomer binding to neurons, reduces synapse loss, restores synaptic protein 
expression, facilitates oligomer clearance into the CSF, and restores cognitive function. The 
ability of CT1812 to improve cognitive performance in transgenic mice while not affecting the 
performance of wild-type mice supports a specific effect of CT1812 on the pathological pathway 
of AD: this disease-selective mechanism may provide an advantage over other therapeutic 
approaches that impact brain function more widely.  
Preliminary evidence from the phase1b/2a clinical trial reported here supports these findings. 
This study was limited by small patient numbers and short duration of treatment in the COG0102 
trial. Larger studies with additional dose levels will be required to establish dose-response 
relationships with biomarker changes, and distingish both acute and long-term disease modifying 
effects of Ct1812 treatment. While not all proteins and signaling pathways known to be 
dysregulated in AD were affected by treatment with CT1812, several pathways were 
significantly impacted (including cholesterol transport, oxidative stress, complement, and 
synaptic transmission; Fig. 5E). Together, these results provide encouraging evidence of the 
impact of CT1812 on multiple aspects of disease in AD patients and support further development 
of this drug candidate so that the relative benefit and risks of CT1812 can be more thoroughly 
evaluated.  
CT1812 is an investigational therapeutic that has not been reviewed or approved for any use by 
FDA. CT1812 is currently being studied in four randomized, double-blind, placebo-controlled 
phase 2 studies (6 months – 1 year in treatment duration) in patients with mild to moderate AD: 
SNAP (NCT03522129), SPARC (NCT03493282), SHINE (NCT03507790), and SEQUEL. An 
additional 18 month study in 540 early AD patients (MMSE 20-30) is being planned in 
collaboration with the ACTC clinical trial network. The safety and tolerability of CT1812 will 
continue to be explored in all clinical trials. 
Materials and Methods 
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Radioligand binding 
Radioligand competition assays to determine affinity for sigma-2 and sigma-1 receptors were 
performed at Eurofins Cerep SA (Le Bois L'évêque, France) in membranes from Jurkat cells 
(immortalized human T cells). Assays for sigma-2 receptors used 25 nM [3H]1,3-di(2-tolyl) 
guanidine in the presence of 1 μM (+)-pentazocine while assays for sigma-1 receptors used 15 
nM [3H](+)-pentazocine. Non-specific binding in both assays was defined in the presence of 10 
μM haloperidol [82]. Estimated percent receptor occupancy for in vivo behavioral studies (see 
below) was calculated according to the formula 100*(concentration/Ki)/[(concentration/Ki) + 
1)], where Ki is determined by radioligand competition binding (CT1812 = 8.5 nM) [26]. 
Neuronal cultures 
Mixed neuronal and glia cultures were made from embryonic day 18 (E18) Sprague Dawley rat 
brains and grown in poly-D Lysine coated plates for 21 days, as previously described [26,28]. 
All procedures were approved by the Institutional Animal Care and Use and Committee at 
Cognition Therapeutics and were in compliance with the Office of Laboratory Animals Welfare 
and the Guide for the Care and Use of Laboratory Animals, Eighth Edition. Embryos from a 
single rat were pooled to produce a unique dissociated neuronal culture. All analyses described 
below were performed on at least three unique cultures. Healthy cultures typically contain 20%-
35% MAP2-positive neurons. CT1812 was tested in quadruplicate wells for each concentration 
in at least three replicate experiments with data from all experiments pooled for analysis with 
means +/- standard deviation (SD) or standard error of the mean (SEM) as noted.  
AOligomer preparation 
Synthetic human A 1-42 peptide was prepared as previously described [26,28]. Briefly, peptide 
was treated according to published methods to remove any structural assemblies [83,84]. An A 
monomer film was prepared, dissolved, diluted to 100 μM, and incubated at 4 ºC to form 
oligomers. The resulting preparations were centrifuged to remove any insoluble fibrils, and the 
supernate added to cultures. All studies using synthetic oligomers were performed with this 
preparation unless otherwise specified. All lots of A 1-42 are put through a strict quality control 
processes, described previously [26,28], before use in experiments. As previously reported, 
oligomers produced via this method typically range from 25-275 kDa when measured via non-
denatured western blots (Figure 2, [26]). 
Human AD patient (Braak V/VI) and age-matched control hippocampal brain specimens, less 
than 24 hours post-mortem, were obtained from the Brown Brain Bank following previously 
described procedures [26,28]. Tissue was prepared as previously described [26,28]. Briefly, the 
brain tissue was homogenized and centrifuged, supernate were immuno-depleted and 
concentrated to obtain the10-100 kDa size-fractionated oligomers, which were then captured on 
6E10-conjugated agarose columns (Pierce). The released material was desalted and stored at -80 
ºC. Use of postmortem brain specimens met the exemption criteria for DHHS regulations, as 
previously explained [26,28]. 
In vitro trafficking assay 
Vesicular trafficking was measured using an adaptation of a method as previously described 
[26,85]. Neurons were treated with compounds and/or Aβ oligomer preparations (0.086% DMSO 
in culture media) and incubated for 1 to 24 hours at 37ºC in 5% CO2. For prevention studies, 
CT1812 was added at indicated concentrations 1 hour prior to addition of Aβ oligomers. In 
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treatment studies, Aβ oligomers were added 1 hour prior to addition of CT1812. Tetrazolium 
salts (3-(4,5-dimethylthiazol-2yl)-2,5diphenyl tetrazolium bromide, Roche Molecular 
Biochemicals) were added at a final concentration of 0.75 mM and incubated at 37ºC for 60-90 
min. Vesicular formazan remaining in cells was quantified by absorbance spectrometry (590 nm 
with 690 nm subtracted) following extraction with 1.6% Tween-20. All compounds were tested 
in quadruplicate wells for each concentration in at least 8 replicate experiments with data from 
all experiments pooled for analysis with means ± SEM.  
In vitro Aβ binding assay 
Assessment of Aβ oligomer binding was performed as previously described [26,28]. Briefly, 
cultures were either (for prevention studies) treated with CT1812 for 30 minutes, followed by 
synthetic Aβ 1-42 oligomer preparation for 60 min, or (for displacement studies) treated with 
oligomers 30 min prior to the addition of CT1812. Cells were then fixed and labeled for 
immunofluorescent microscopy as previously described [26]. All data for Aβ binding presented 
represents total fluorescent intensity of Aβ label in neurite spots per neuron in relative 
fluorescent units (RFU). Replications and statistical procedures for the quantification of Aβ 
immunofluorescent intensity were previously described [26].  
In vitro synapse counting assay 
Synapse number was quantified using quantitative immunofluorescent microscopy of drebrin-
labeled puncta (Millipore AB-10140) along MAP2-positive neurites (Millipore AB5543) as 
previously described [26]. Additional immunofluorescent labeling was performed on neuronal 
cultures for SYT-1 (Synaptic Systems #105 103) and for neurogranin (Abcam ab23570). 
Human tissue ex vivo A displacement 
Displacement of Aβ from human tissue was assessed as previously described [28]. Briefly, 
brains from human AD patients were obtained through the Massachusetts Alzheimer’s Disease 
Research Center and Massachusetts General Hospital (MGH) Neuropathology Department. 
Experiments using human brain were reviewed and approved by the Academic and Clinical 
Central Office for Research and Development medical research ethics committee, a joint office 
of the University of Edinburgh and NHS Lothian (approval 15-HV-016). Parahippocampal gyrus 
sections (one section per specimen per condition) were incubated with 0.1, 1.0, 10, or 15 µM 
CT1812 in PBS, or vehicle for 60 min as previously described [26] and then labeled with an 
antibody specific to A (AW-7, gift from Dominic Walsh [86]). Dense core amyloid plaques and 
neurofibrillary tangles were labeled with 0.05% Thioflavin-S (Sigma Aldrich) in 50% ethanol for 
8 min before treatment with 80% ethanol for 30 s. Images were analyzed in ImageJ [87] using a 
custom macro (described in Fig. S4 in Izzo, et al. 2014b [28]). A total of 105 to 279 plaques 
were analyzed for each treatment from eight different donors and average intensities for each 
specimen were calculated. The median intensity value was calculated for each specimen and 
subjected to multivariate correlation analysis as previously described [28]. Determination of total 
A concentration eluted from human donor brain tissue was performed using a high sensitivity, 
human Beta Amyloid (1-42) ELISA Kit (Wako, cat # 296-64401) which uses [BAN50/BC05 
(Fab')]. 
Western blot analysis of A oligomers 
Non-denaturing western blot conditions were employed to avoid the generation of A assembly 
and disassembly artifacts, as previously described [26]. Briefly, baseline and end of study CSF 
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samples from AD patients participating in clinical trial COG0102 were collected in 
polypropylene tubes in 500 µL and frozen at -80ºC until analysis. Upon receipt, the samples 
were thawed and quickly aliquoted into polypropylene tubes coated with isotonic human serum 
albumin and refrozen until analysis by native western gels. Because the effects of blood on A 
oligomer formation in CSF is unknown, an aliquot of each patient sample was pre-analyzed on a 
western blot using luminol and horseradish peroxide to test for the presence of heme. Final 
western gel analysis was performed on samples excluding those containing hemolyzed blood.  
Samples were run on Tris-HCl nondenaturing gels, transferred to nitrocellulose and probed with 
82E1 mouse monoclonal A antibody (IBL America, Minneapolis, MN) and visualized by 
chemiluminescence after detection using a goat anti mouse IgG-horseradish peroxidase 
secondary antibody (Millipore, Burlington, MA). All reagents were filtered through 0.1 micron 
filters to eliminate background debris. Band intensities on the gels were quantified using an 
Alpha Innotech image system and Alpha View software (ProteinSimple, San Jose, CA). Each 
patient’s sample at day 28 was normalized as a percent of that patient’s own baseline value. 
Measurement of A using microimmunoelectrodes 
APP/PS1+/− hemizygous mice [42] were bred to wildtype C3H/B6 mice (The Jackson 
Laboratory) and the APP/PS1+/− offspring were used for experiments at 12 months of age. Male 
and female littermate mice were distributed between experimental groups.  
MIEs, which can measure Aβ every 60 seconds for up to three hours, were prepared similar to 
previously described methods [40]. Carbon fiber microelectrodes were used as the platform 
sensor due to their high signal to noise ratio, biological compatibility, and miniature size [88], 
and ability to sensitively detect tyrosine oxidation (66). Electrodes were coated with antibodies 
specific for Aβ monomer (HJ2)[40] or for oligomers (A11)[41] and inserted into hippocampus to 
measure brain ISF Aβ levels or into lateral ventricles to measure CSF Aβ levels.  
Electrodes were pre-calibrated in vitro (see supplementary methods). In addition to the MIE, a 
stainless-steel bone screw used as a counter electrode and an Ag/AgCl reference electrode 
(InVivo Metrics, CA USA) were implanted into the brains of 12-month old APP/PS1+/- 
transgenic mice. All electrodes were stereotaxically implanted under isofluorane anesthesia. 
Mice were placed on a heating pad to maintain body temperature and repetitive SWV scans were 
run every 60 s for up to 180 min using a CH Instruments 830D Electrochemical Analyzer with 
PicoAmp booster. The stereotax was enclosed in a faraday cage to reduce electrical noise. 
CT1812 or vehicle were administered i.v. via tail vein injection at the concentrations noted. All 
procedures were approved by the Institutional Animal Care and Use and Committee at 
Washington University, St Louis, and were in compliance with the Office of Laboratory Animals 
Welfare and the Guide for the Care and Use of Laboratory Animals, Eighth Edition. 
More detail can be found in the supplementary methods section.  
Behavioral Studies 
All procedures were approved by the Institutional Animal Care and Use and Committee at 
Stanford University and were in compliance with the Office of Laboratory Animal Welfare and 
the Guide for the Care and Use of Laboratory Animals, Eighth Edition. Testing of male 
transgenic Thy1 huAPPSwe/Lnd+ mice in the Morris water maze, Y-Maze, or fear conditioning 
tasks was done according to published methods [45,46]. Studies were designed with four arms: 
wild-type, vehicle treated (n = 12); wild type, CT1812 treated (n = 12); transgenic, vehicle 
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treated (n = 12); transgenic, CT1812 treated (n = 13). All procedures were approved by the 
Institutional Animal Care and Use and Committee at Stanford University and were in 
compliance with the Office of Laboratory Animals Welfare and the Guide for the Care and Use 
of Laboratory Animals, Eighth Edition. 
To measure brain concentration of drugs, brains were homogenized in 1 ml PBS per gram of 
brain tissue using a handheld homogenizer. Brain homogenate was then extracted with three 
volumes of ice cold methanol on ice for 15 minutes and centrifuged for 15 min. The supernates 
were analyzed by LC/MS/MS. Samples were compared to a calibration curve prepared in a 
similar manner by spiking blank control homogenate with standards prepared in DMSO and then 
extracted as above.  
Clinical trial of CT1812 in mild-to-moderate AD patients 
The clinical trial was performed at six sites in Australia and administered by Neuroscience Trials 
Australia. The study protocol was approved by the Human Research Ethics Committee at the 
Alfred Hospital, Melbourne, Australia, and was conducted in accordance with the Declaration of 
Helsinki and Good Clinical Practice guidelines. All subjects provided written informed consent 
before participating. Mild to moderate (MMSE 18-26) AD patients (N=19) were randomized to 
one of three doses of CT1812 (90, 280 or 560 mg Q.D.) or placebo given orally once daily for 28 
days (4 weeks) to determine safety and tolerability (COG0102, for full listing of inclusion and 
exclusion criteria see ClinicalTrials.gov NCT02907567). Exploratory outcomes included CSF 
protein expression measured at baseline (Day 0) and end of treatment (Day 28). Missing samples 
(declined or failed spinal taps) and variable CSF sample volumes reduced the number of matched 
baseline and day 28 patient CSF samples available for subsequent analysis.   
ELISA measurement of CSF synaptic proteins  
CSF levels of Aβ40, Aβ42, T-tau and P-tau were measured using the INNOTEST enzyme-linked 
immunosorbent assays (ELISA) (Fujirebio, Ghent, Belgium), following the recommendations by 
the manufacturer. Neurofilament light was measured using an ELISA from Uhman Diagnostics 
(Umea, Sweden). These analyses were conducted by board-certified laboratory technicians 
according to Swedish Board for Accreditation and Conformity Assessment (SWEDAC)-
approved protocols. Neurogranin CSF concentrations were measured using an in-house ELISA 
method based on the Ng2 and Ng22 antibodies, as described previously in detail [89]. 
Concentrations of SNAP-25 in CSF were measured using immunoprecipitation combined with 
mass spectrometry (IP-MS) as described previously [90]. 
LC-MS/MS measurement of CSF synaptic proteins and phosphorylated tau fragments 
Synaptotagmin-1 measurements were obtained as part of unbiased LC-MS/MS proteomics 
analysis of AD patient CSF samples at Caprion Biosciences using published methods [91]. 
Additional unbiased proteomics analyses including an enrichment for phospho-proteome were 
performed on CSF samples at Proteome Sciences using the protocols as previously published 
[61,92] with minor modifications. For statistical analysis of unbiased LC-MS-MS proteomics, a 
linear mixed model was used. Detailed methods can be found in the supplementary methods 
section.  
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Fig. 1. CT1812 is a selective sigma-2 receptor ligand that prevents and treats Aβ oligomer-
induced membrane trafficking deficits. (A) CT1812 binds sigma-2 receptors with a 8.5 nM Kd 
and sigma-1 receptors with a 63 nM Kd as measured in radioligand displacement studies (n=2; 
error bars = SD). (B) Effects of synthetic Aβ oligomers on vesicle trafficking in primary cultures 
of neurons and glia. Quantification is shown of the amount of formazan within intracellular 
vesicles in Aβ oligomer-treated (red dot) or vehicle-treated (blue square) conditions, and the 
dose-dependent restoration of trafficking rate to normal vehicle-treated values following CT1812 
addition 1 hour before addition of Aβ oligomers (gray squares, EC50 = 6.7 µM, n = 11 
experiments) or 1 hour after addition of Aβ oligomers (black squares, EC50 = 0.36 µM, n = 12 
experiments). Vesicle trafficking was assayed 24 hours after addition of Aβ oligomers (1.75 µM, 
total peptide) (error bars = SEM). N represents the number of replicate experiments from 
separate cell culture preparations. (C) Human AD brain derived Aβ oligomers (1-hour treatment) 
caused a 27 ± 11% (SD) (p < 0.001, n=3) decrease in trafficking rate in cultured neurons and 
glia. Pretreatment of cultures for 1 hour with 15 µM CT1812 before addition of human derived 
Aβ oligomers blocked the trafficking deficits (p < 0.001 for Aβ Oligomers vs. Aβ Oligomers + 
CT1812, ANOVA with Tukey’s post hoc test, n = 3 experiments). Each point represents results 







Fig. 2. CT1812 prevents Aβ oligomer binding to and displaces bound oligomers from 
neuronal receptors, leading to restoration of synaptic density and protein expression in 
cultured mouse neurons. (A) Aβ oligomers (750 nM, >80% of Kd) bind specifically and 
saturably to a single receptor site on some, but not all, neurons in mature (>21 DIV) primary 
hippocampal and cortical neuronal cultures. (B) CT1812 [10 uM] prevents Aβ binding by 59 ± 
8% (SEM) when added 1 hour prior to addition of Aβ oligomers. (C) CT1812 [10 uM] displaces 
Aβ oligomer binding by 42 ± 9% (SEM) when added 1 hour after addition of Aβ oligomers. 
Scale bar = 20 microns. (D) CT1812 prevents binding and more than doubles the Kd of oligomer 
binding, from 430 nM (at 0 M CT1812) to 1120 nM (at 10 M CT1812) (n=6; error bars = 
SEM). (E) CT1812 displaces binding and nearly doubles the Kd of oligomer binding, from 610 
nM (at 0 M CT1812) to 1160 nM (for 10 M CT1812) (n=6; error bars = SEM). (F, top) Aβ 
oligomers bind to receptors at neuronal synapses (red, 6E10 immunodetection), resulting in a 
significant loss of synapses (green, drebrin immunodetection, 12.8 ± 2.6% (SEM) decrease in 
synapse density, p<0.01 vs. vehicle-treated, Student’s t-test [G]; the blue square represents 
synapse density in vehicle-treated neurons.) (F, bottom) CT1812 displaces bound Aβ oligomers 
and restores synaptic numbers to normal in a dose-dependent manner. Scale bar = 5 microns. (G) 
CT1812 restores synapse number to normal whether added before (prevention, EC50 = 68 nM) 
or after (treatment, EC50 = 127nM) Aβ oligomers (*p<0.5 vs. Aβ oligomers alone for both 
conditions, Student’s t-test, error bars = SEM). Treatment with CT1812 restores synaptic protein 
expression in cultured rat neurons. (H) Neurogranin is expressed at high levels in postsynaptic 
dendrites and synapses in a subset of neurons in primary hippocampal/cortical cultures. (I) 
Addition of Aβ oligomers (0.75 μM, 24 hours) cause a 28% loss of neurons expressing high 
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levels of neurogranin (p = 0.014). (J) Treatment with 4.8 μM CT1812 1 hr after addition of Aβ 
oligomers restores the expression of neurogranin to normal levels (Aβ oligomers vs. Aβ 
oligomers + CT1812 p = 0.031, vehicle vs. Aβ oligomers + CT1812, n.s., ANOVA with Tukey’s 
post hoc test, n = 20). (K) Synaptotagmin-1 is expressed in presynaptic terminals. (L) Addition 
of Aβ oligomers (3.5 μM, 48 hours) cause a 37% loss of synaptotagmin-1 presynaptic terminals 
in primary hippocampal/cortical cultures (p = 0.0068, N = 24) (M) Treatment with 4.8 μM 
CT1812 1 hr after addition of Aβ oligomers blocks these losses and restores expression of 
synaptotagmin-1 levels (vehicle vs. Aβ oligomers + CT1812, n.s). (H-M) ANOVA with Tukey’s 
post hoc test, n = 20. For all cell culture experiments, n represents the number of replicate 
experiments from separate cell culture preparations, and data points represent means ± SD or 




Fig 3. CT1812 treatment displaces Aβ oligomers from mouse hippocampal receptors and 
postmortem AD human patient tissue and facilitates their clearance into CSF. (A, B) 
Microimmunoelectrodes (MIE) coated with oligomer-specific antibody A11 (A) or mAβ40 
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antibody HJ2 (B) in 12-month-old transgenic hAPP/PS1 mice detect soluble Aβ in the 
hippocampal interstitial fluid (ISF). (A) Following i.v. injection of 0.3 or 3 mg/kg CT1812 
(vertical dashed line), soluble Aβ oligomers are significantly elevated in hippocampal ISF in 
CT1812-treated mice (n=7) compared to vehicle-treated mice (n=4, *** p< 0.001, **** 
p<0.0001, two-way ANOVA with Sidak’s post hoc test for effect of drug vs. vehicle.) (B) 
CT1812 treatment does not cause a change in total Aβ levels in the hippocampus (n=5) 
compared to vehicle treatment (n=4). (C-E) Aβ oligomers displaced from post-mortem brain 
tissue sections from 8 AD patients were quantified by ELISA (D) and native western blots (C 
[representative individual patient], E), and show the expected dose-dependent increase in 
concentration in CT1812-treated compared to the vehicle-treated condition. For western blots, 
the sum of the intensity of discrete Aβ protein bands at 22, 33, 43, 48 and 85 Kd was quantified 
for each donor tissue section (C). In (D) and (E), values for A measured by ELISA for each 
brain tissue section and for intensity of western blot bands for each brain tissue section 
normalized to vehicle-treated controls (dashed line) from the same donor are shown (*p < 0.05, 
ANOVA with Tukey’s post hoc test for each treatment vs vehicle treated controls). (F 
[representative individual patient], G, H) Aβ oligomers (red) located in a 2 M halo surrounding 
compact thioflavin-S positive plaques (green) are displaced from frozen postmortem human AD 
brain tissue sections (N=5 patients) by CT1812 in a dose-dependent manner normalized to 
vehicle treated brain sections (dashed line) from the same individual (*p < 0.05, ANOVA with 
Tukey’s post hoc test for each CT1812-treated vs vehicle-treated controls). (H) Aβ intensity 
within plaques does not change. Scale bar = 20 M. (I, J) Microimmunoelectrodes coated with 
oligomer-specific antibody A11 (I) or pan-Aβ antibody HJ2 (J) in 12 month old transgenic 
hAPP/PS1 mice detect soluble Aβ in the lateral ventricle cerebrospinal fluid (CSF). (I) 
Following i.v. injection of 0.3 (n=7) or 3 (n=5) mg/kg CT1812 (vertical dashed line), soluble Aβ 
oligomers are significantly elevated in lateral ventricle CSF compared to vehicle-treated mice 
(n=5). (J) CT1812 treatment (n=5) did not cause a change in Aβ monomer levels in the CSF 
compared to vehicle treatment (n=4). *** p< 0.001, **** p<0.0001, two-way ANOVA Sidak’s 






Fig. 4. Treatment with CT1812 improves learning and memory deficits in transgenic 
Alzheimer’s mice. (A) Transgenic Thy-1 huAPPSwe/Ldn+ male mice treated with CT1812 (Tg 
+ CT1812) learn the Morris water maze task significantly better than do transgenic vehicle-
treated mice (Tg + vehicle; p=0.016, two-way repeated measures ANOVA, Bonferroni post hoc 
*p < 0.5; error bars = SEM). CT1812 treatment does not affect non-transgenic animal 
performance (nTg + CT1812). (B) Transgenic mice treated with CT1812 remember previous 
arms entered in the Y maze task significantly better (p=0.013, Student’s t test) than chance 
(dashed line), but transgenic vehicle-treated animals do not (nTg + vehicle, 62.7 ± SD 12.2%; Tg 
+ vehicle, 56.1 ± SD 9.2%; Tg + CT1812, 58.5 ± SD 9.4%; nTg + CT1812, 65.3 ± SD 6.0%). 
(C) Transgenic mice show deficits in the Contextual Fear Conditioning test (p = 0.037, Student’s 
t-test), while transgenic and non-transgenic mice treated with CT1812 do not (nTg + vehicle, 
52.5 ± SD 5.4%; Tg + vehicle, 37.9 ± SD 6.4%; Tg + CT1812, 44.6 ± SD 6.5%; nTg + CT1812, 
50.9 ± SD 5.1%). (Each data point represents an individual mouse.) (D) Plasma and brain 





Fig. 5. CT1812 treatment significantly impacts CSF biomarkers of target engagement and 
disease-related biology. Protein concentrations in CSF samples from AD patients in a 28 day 
phase 1b/2a clinical trial of CT1812 vs. placebo were measured via ELISA, LC-MS/MS or gel 
electrophoresis. (A) After 28 days the concentration of Aβ oligomers measured via western blot 
in CT1812-treated AD patient CSF increases compared to the patient’s own baseline and vs. 
placebo (p=0.014, Student’s t test, n = 3 placebo, 10 CT1812-treated), providing supporting 
evidence of clinical target engagement. At day 28 of the study, the concentration of synaptic 
damage proteins neurogranin (B, measured by ELISA) and synaptotagmin-1 (C, measured by 
LC-MS/MS) decreases compared to the patient’s own baseline and vs. placebo (p=0.050 
ANCOVA, n = 5 placebo, 11 CT1812-treated; and F1,12 = 8.8, p = 0.011, n = 4 placebo, 9 
CT1812-treated, respectively) providing evidence of a positive effect on synapses in patients 
with AD. (A, B and C) Data from individual patients are displayed. These changes are 
corroborated (D) by significant expression changes (p<0.05) in multiple synaptic proteome 
proteins in the CSF measured by unbiased LC-MS/MS in AD patients treated for 28 days with 
CT1812 vs. placebo. (E) CSF Proteomics identifies a subset of proteins significantly altered with 
CT1812 that have been reported to be significantly regulated in AD [93]. Data are expressed as 
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mean % change in protein concentration in CSF from CT1812 treated (n=11) versus placebo 
(n=4) (blue) and AD versus control to illustrate how these proteins are altered in AD relative to 
cognitively normal age-matched controls. All analytes shown are significantly regulated (p<0.05) 
in AD patients vs. control  [53] and in the present study. (F) Following 28 days of treatment, the 
abundance of six tau phosphorylation peptides decreased by 30% (the threshold for noise 
distribution), or more after treatment with CT1812 compared to placebo (T52, T205, S262, S263, 
S285, S305) while one site increased more than 30% (S191), but the concentration of 
unphosphorylated tau did not change, providing evidence of CT1812 impact on pathological 
disease signaling. Colored bars represent amino acid sites within tau that are phosphorylated by 






Fig. 6. Hypothesized mechanism of action of CT1812: synaptoprotective displacement of 
toxic Aβ oligomers from neurons. (A) In the absence of Aβ oligomers, pre- and post-synaptic 
proteins such as synaptotagmin-1 and neurogranin are expressed at normal levels. (B) The 
sigma-2 receptor complex tightly regulates the oligomer receptor complex by stabilizing plasma 
membrane expression of oligomer receptor component proteins. (C) Oligomer binding results in 
changing expression/localization of synapse associated proteins, spine loss, and memory failure, 
as well as upregulation of the sigma-2 receptor complex. (D) Fragmented pre- and post-synaptic 
proteins such as synaptotagmin-1 and neurogranin move into ISF and then CSF. (E) CT1812 
binds to the sigma-2 receptor ligand binding site within the sigma-2 receptor complex, acting as 
a negative allosteric modulator of Aβ oligomer binding. This destabilizes the oligomer binding 
site and displaces oligomers from synapses without affecting normal synapse protein function. 
(F) Synapse number and memory are restored to normal levels. 
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Supplementary Materials and Methods 
MIE preparation 
A single length of carbon fiber (5μm diameter, GoodFellow Corp, England) was aspirated into a 
glass capillary tube (0.4 mm inner diameter, 4” length, A-M Systems, WA, USA), pulled using a 
pipette puller (Narishige PE-22, Japan) and attached to an insulated silver wire using conductive 
silver adhesive paste (Ted Pella, CA, USA). The junction between the wire and the glass 
capillary tube was sealed using heat shrink tubing (NTE Electronics, NJ, USA). The carbon fiber 
was cut to a length of 30-60 μm. To enhance binding of the capture antibody, the 
microelectrodes were pretreated using a triangular waveform from 0 to 3V for 20 s, held at -0.8 
V for 5 sec, and then held at 1.5 V for 10 sec in PBS. Activation of carboxylic groups on the 
carbon fiber surface was achieved by application of 0.4 M of EDC and 0.1 M of NHSS solutions 
(Thermo Scientific, IL, USA) to form a semi-stable reactive amine NHS ester. The activated 
microelectrodes were placed in a solution of 10 ug/ml A11 antibody (Invitrogen, Rockford, IL, 
USA) or HJ2 (Washington University, St. Louis, USA) and incubated at room temp for 10 min 
and then 4 °C overnight. Following antibody attachment, MIEs were incubated with 0.05% 
ethanolamine to deactivate reactive amine sites then 1% BSA to block non-specific protein 
binding sites. 
In vitro calibration of the MIEs  
In vitro calibration of the MIEs before experiments were conducted using a CH Instruments 
660D Electrochemical Workstation with PicoAmp booster (CH Instruments Inc, TX, USA). A 
conventional three-electrode cell consisting of an Ag/AgCl reference electrode (1M KCL), and a 
platinum wire as a counter electrode was used in all experimental procedures. Oligomers were 
prepared by incubating 100 uM synthetic human Aβ42 (American Peptide Co, CA, USA) 1:50 in 
10 mM HCl, 150 mM NaCl in ddH2O at 4C for 16 hours. Calibration curve concentrations were 
prepared in 5-fold serial dilutions ranging from 16 pg/ml to .204 fg/ml in 1% BSA for Aβ 
oligomers, and from 200 ng/ml to 512 fg/ml for Aβ monomers. Square Wave 
Voltammetry (SWV) was used to monitor the response of the electrode in different 
concentrations of Aβ oligomers. SWV parameters used were: Init E (V) = 0; Final E (V) = 1.2; 
Incr E (V) = 0.004; Amplitude (V) = 0.04; Frequency (Hz) = 15.  
In vivo MIE experiments 
The APP/PS1 mice used in these experiments contain a PS1ΔE9 mutation and human APP 
Swedish mutation that were inserted into a single locus. Animals were screened for the PS1 and 
APP transgenes by polymerase chain reaction from tail DNA. All electrodes used for MIE 
studies were calibrated against known concentrations of Aβ oligomers prior to the experiment, 
and only MIEs showing increasing response to increasing concentrations of Aβ oligomers in 
vitro were used for in vivo experiments. MIEs were inserted into the hippocampus at 
coordinates: A/P -3.1 mm, M/L 2.6 mm, and D/V -1.7 mm, or into the lateral ventricle at 
coordinates: A/P -0.6 mm, M/L 1.2 mm, and D/V -1.6 mm.  
Statistical analysis of MIE experiments 
All in vitro measurements were carried out in triplicate and the average of the three SWV scans 
was used for analysis. All current responses recorded were subtracted from background and fit to 
baseline for peak analysis using CH Instruments software. Results are expressed as mean ± SEM 
 35 
Differences in clearance rates between groups were analyzed in GraphPad Prism software using 
T-tests, and Repeated Measures ANOVA with Bonferroni post hoc tests were used to analyze 
percent changes in baseline levels over time. Statistical significance in all analyses was set at p < 
0.05.  
Combined tissue and CSF analysis of synaptic proteins and phosphorylated tau 
Tissue-enhanced analysis of CSF protein expression was performed using TMTcalibrator™. 
CSF samples were provided under partially blinded conditions: samples were grouped according 
to treatment type, but the identity of the placebo- or drug-treated group was undisclosed. Frozen 
brain tissue from three regions (frontal, parietal cortices and cingulate gyrus) from the same post-
mortem brain (Caucasian, female, 67 years old, APOE E3/E4), confirmed as being Braak Stage 
IV-VI (Bielchowski silver stain) with abundant neuritic plaques and neurofibrillary tangles, were 
purchased from BioIVT (Burgess Hill, UK) for use as the calibrant/trigger. Approximately 500 
mg of each brain tissue was lysed (8M urea, 75 mM NaCl, 80 mM Tris; pH 8.2 containing 
phosphatase and protease inhibitors). Tissue debris was removed by centrifugation at 12000g, 
4°C for 2x10 min and supernatants containing 27 mg total protein from each lysate were pooled, 
diluted to a concentration of 3 mg/ml, aliquoted and stored at -80°C.  
For each TMT® 11plex eight individual CSF samples containing 150 µg total protein along with 
three replicate aliquots of 700 µg total protein of the brain lysate were processed in parallel. 
Proteins were denatured in 100 mM tetraethylammonium bromide (TEAB) buffer and 0.1% 
sodium dodecyl sulfate (SDS), reduced with 1 mM tris (2- carboxyethyl) phosphine (TCEP) and 
incubation at 55°C for 60 min, and finally alkylated with 7.5 mM iodoacetamide at room 
temperature for 60 min. Proteins were digested overnight at 37°C in ~1:25 ratio trypsin to total 
protein weight and subsequently labeled using TMT® 11plex reagents (15 mM), incubated at 
room temperature for 1 hour, and quenched by the addition of 0.25% hydroxylamine for 15 min. 
Each of the 11 individual TMT® labelled samples (8 x CSF, 3 x brain) were the pooled to form 
the analytical TMT® 11plex sample. For further processing, each TMT® 11plex sample was split 
into aliquots of 1 x 50 µg (quality control), 2 x 100 µg (total protein analysis) and 1 x 3,050 µg 
(phosphoproteomics). 
Phosphopeptide Enrichment: Each TMT® 11plex sample (~3050 µg) was enriched for 
phosphopeptides using the High Select™ FeNTA Phosphopeptide Enrichment Kit (Thermo 
Scientific Pierce, cat. no. A32992) according to manufacturer`s instructions.  
Basic Reversed-Phase Fractionation: Basic reversed-phase (bRP) fractionation was conducted in 
parallel for both non-enriched peptides the enriched phosphopeptides from each TMT® 11plex 
using Pierce™ High pH Reversed-Phase Peptide Fractionation Kit (Thermo Scientific, cat. no. 
84868) according to manufacturer`s instructions and six individual fractions produced for each of 
the non-enriched and phosphopeptide enriched .  
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS): The 12 bRP fractions were 
analysed by LC-MS/MS using the EASY-nLC 1000 system coupled to an Orbitrap Fusion™ 
Tribrid™ Mass Spectrometer (both Thermo Scientific). Re-suspended peptides were loaded onto 
a nanoViper C18 Acclaim PepMap 100 pre-column (Thermo Scientific) and resolved using an 
increasing gradient of acetonitrile in 0.1% Formic acid through a 50 cm PepMap RSLC 
analytical column (Thermo Scientific) at a flow rate of 200 nL/min. LC gradient started with 
10% ACN up to 30% ACN over 160min and was increased to 90% ACN over 10min at a flow 
rate of 300nL/min. Peptide mass spectra were acquired throughout the entire chromatographic 
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run (180 minutes), using top speed higher collision induced dissociation (HCD) Fourier-
transform mass spectrometry (FTMS) MS2 scans at 60,000 resolving power @ 400 mass over 
charge (m/z), following each FTMS scan (120,000 resolving power @ 400 m/z).  
Computational Mass Spectrometry: In total 64 separate raw files were submitted to Proteome 
Discoverer (PD) v2.1 (Thermo Scientific) using the Spectrum Files node. The Spectrum Selector 
was set to its default values while the SEQUEST HT node was suitably set up to search data 
against the human FASTA UniProtKB/SwissProt database (version November 2018). Up to ten 
sequence matches per spectrum were permitted. The reporter ions quantifier node was set up to 
measure the raw intensity values for TMT® 11plex mono-isotopic ions (126, 127N, 127C, 128N, 
128C, 129N, 129C, 130N, 130C, 131, 131C). The SEQUEST HT search engine was 
programmed to search for tryptic peptides (with two missed cleavages) and with static 
modifications of carbamidomethyl (C), TMT6plex (K), and TMT6plex (NTerm). Dynamic 
modifications were set to phosphorylation (STY), deamidation (N/Q) and oxidation (M). 
Precursor mass tolerance was set to 20 parts per million (ppm) and fragment (b and y ions) mass 
tolerance to 0.02Da. Spectra were also searched using the ptmRS-2.0 (fragment mass tolerance 
of 0.02Da, considering neutral loss peaks for collision induced dissociation (CID) and HCD) and 
Percolator nodes. The ptmRS node scored each phosphate group (assigned to serine, threonine or 
tyrosine residues) with a local site confidence probability score within each phosphorylated 
peptide sequence. A score greater than or equal to 75% was considered as an unambiguous site 
assignment, while scores less than 75% were considered ambiguous [96]. All raw intensity 
values were exported to tab delimited text files for later processing and filtering using in-house 
software. Grouped protein results were exported to tab-delimited “Multi-consensus.txt files”, 
filtered at 1% false discovery rate (FDR) (PSM level) and 1 x Rank 1 peptide per protein. Protein 
grouping was performed using the Parsimony Principle option in the Protein Grouping area 
within PD. More information about the protein grouping algorithm can be found in the Proteome 
Discoverer (PD) Version 2.1 User Guide (version A, July 2015). Results were filtered at 1% 
FDR (PSM level and Protein level) and exported to tab-delimited “Multi-consensus.txt files.”  
Graphical outputs and final table of results were produced using a selection of automated scripts 
that had been written in R. The log2 ratio (AD group median CSF signal intensity divided by the 
control group median CSF signal intensity) was graphed as a percent difference. The noise 
distribution cutoff was determined to be 30% (up- or down-regulation). 
For visualizaton of phospho-site inter-relationships, hierarchical clustering (Pearson) was 
performed for both rows and columns using Average Linkage using 
https://software.broadinstitute.org/morpheus/. 
Pathway analysis was performed using IPA (v51963813, QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis), Metacore (v19.4 
build 69900, and STRING (v11] [97]. 
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Supplementary Fig. 1 Counterscreening reveals that CT1812 is a selective sigma-2 ligand. 
Structure of CT1812 fumarate is shown. CT1812 is 100-fold selective for sigma-2 receptors vs. 
72 other receptors.  
 
  




Assay type Binding Ki 
(nM) 
Sigma-2 0148 Radioligand binding 8.5 
Sigma-1 0889 Radioligand binding 63 
Binding Activity > 1,000 nM  
Target Catalog No. Target Catalog No. Target Catalog No. 
M1 091 NK3 0104 CAMK4 1582 
M2 093 Y1 0106 CDK/p35 2877 
M3 095 Y2 0107 EGFR kinase 2865 
Ca+2 Channel 0163 NTS1 0109 EphA4 kinase 1702 
NE Transporter 0355 Kapa opioid 1971 EphB2 kinase 3054 
DA transporter 0052 Delta 2 opioid  0114 EphB4 kinase 3059 
5-HT transporter 0439 Mu Opioid 0118 FAK 3065 
Adenosine Transporter 0007 N Opioid 0358 Choline Transporter 1552 
Adenosine 1 0002 Sst 0149 FGFR1 kinase 2868 
Adenosine A2A 0004 VPAC1 0157 FGFR3 kinase 2894 
AdenosineA3 0006 V1a 0159 FGFR4 kinase 2895 
ATP1 0024 Kv channel 0166 Fyn kinase 0212 
BZD 0028 SKCa channel 0167 HER/ErbB2 kinase 1598 
B2 0033 Cl channel 0170 IGF1R 3061 
CB1 0036 AMPA 0064 IRK 2898 
CCK1 0039 GABA Transporter 0060 GSK3β 2879 
ETA 0054 NMDA 0066 PKA 2927 
GABA 0057 Glycine 0068 PKCα 0348 
CXCR2 0419 N α4β2  3029 PKCβ1 2888 
GAL2 0410 N α7 3010 PKCβ2 2750 
CCR1 0361 PCP 0124 PKCγ 0350 
H1 0870 NMDA 0066 RAF-1 kinase 2936 
H2 1208 Kainate 0065 Src kinase 2907 
MC4 0420 AMPKinaseα 1572 mTOR kinase 2941 
MT1 1538 CAMK1α 2739 TRKA 2901 
NK2 0102 CAMK2α 3024 Na+ Channel (site2) 0169 
Activity EC50 > 1,000 nM 
Target Catalog No. Target Catalog No. Target Catalog No. 
alpha 1A (agonist) 1500 5HT2A (agonist) 1023 D1 (antagonist) 1686 
alpha 1B (agonist) 1901 5HT2B (agonist) 1377 D3 (antagonist) 684 
alpha 2A agonist) 2558 5HT2C (agonist) 1221 D2S (antagonist) 2569 
alpha 2B (agonist) 1813 5HT4e (agonist) 1044 D4.4 (antagonist) 684 
alpha 2C (agonist) 1736 5HT6 (agonist) 1627 5HT1 A (antagonist) 2101 
Beta1 (agonist) 1605 5HT7 (agonist) 1661 5HT1B (antagonist) 2604 
Beta 2 (agonist) 1976 alpha 1A (antagonist) 1501 5HT2A (antagonist) 1024 
Beta 3 (agonist) 2189 alpha 1B (antagonist) 1902 5HT2B (antagonist) 1812 
D1 (agonist) 1685 alpha 2A (antagonist) 2559 5HT2C (antagonist) 3199 
D2S (agonist) 2566 alpha 2B (antagonist) 1814 5HT4e (antagonist) 1045 
D3 (agonist) 0683 alpha 2C (antagonist) 1737 5HT6 (antagonist) 1628 
D4.4 (agonist) 1699 Beta1 (antagonist) 1606 5HT7 (antagonist) 1662 
5HT1A (agonist) 2093 Beta 2 (antagonist) 1977   





Supplementary Fig. 2. CT1812 reduction of Aβ oligomer presence is not reliant upon 
oligomer dissociation or inhibition of assembly. (A) One-site ELISA specific for oligomeric 
forms of Aβ 1-42. Preformed oligomers were incubated for 18 hours in the presence of 
increasing concentrations of compounds followed by assay for oligomeric Aβ remaining in 
solution. Aβ dissociates slowly over time on its own. The dissociation is enhanced by 2,5-
Dihydroxybenzoic acid (2,5 DHB) [98] while Gallic acid stabilizes oligomers and prevents 
dissociation (data not shown). CT1812 (Fumarate salt) and a Na+Fumarate control have no effect 
on dissociation. All values are normalized to 100% for vehicle control, except for the point for 
incubation time = 0, which represents starting oligomer concentration assayed before incubation. 
Error bars = SD. (B) Aβ 1-42 monomer was allowed to assemble into oligomers in the presence 
of increasing concentrations of compounds for 18 hours before being assayed for Aβ oligomers. 
Assembly of oligomers is inhibited by Tween20 [99], 5,7-diBr-8OH quinoline [100] but not by 






Supplementary Fig. 3. Microimmunoelectrode technology detects changes in Aβ oligomer 
concentration in CSF and brain. As previously published [40], this microimmunoelectrode 
(MIE) technology measures brain ISF levels of Aβ each minute in living 12 month old APP/PS1 
mice. Microelectrodes can be coated with antibodies specific for Aβ40 monomer (HJ2) or 
oligomers (A11) and inserted into hippocampus to measure brain ISF Aβ levels or into lateral 
ventricles to measure CSF Aβ levels. (A) In vitro, Aβ aggregates as measured by A11 MIEs 
detect a robust signal in a solution of mixed Aβ42 oligomers and fibrils but negligible signal in a 
solution of Aβ42 monomer. (B) A11 MIE does not detect Aβ aggregates if guanidine is included 
to prevent their formation; however, the Aβ42 MIE detects comparable levels of total Aβ42 
present. (C) A11 MIEs detect a rapid increase in signal as synthetic Aβ aggregates over 80 
minutes at 37C in vitro. (D) Signal on the MIE is tightly correlated with the levels of soluble 
aggregates over time as assessed by native-PAGE/western blot (Pearson’s r= 0.91; p=0.0127). 
(E) In the brains of aged APP/PS1 mice, the A11 MIE detects a low level of Aβ aggregates at 
baseline, which increases gradually by 2-fold over 60 minutes following 30 mg/kg PTX-induced 
synaptic activity (n=4 per/group). (F) From previous PK studies in wild-type mice, a single i.v. 
dose of CT1812 (0.3 mg/kg, or 3.0 mg/kg; sigma-2 receptor Ki = 8.5 nM) results in a rapid rise 
in brain concentration that remains above 80% estimated receptor occupancy levels for >90 
minutes. Horizontal lines mark concentrations of CT1812 equivalent to theoretical occupancy of 







Supplementary Fig. 4. Validation of western blotting method for detection of Aβ oligomers. 
(A-B) Blocking tubes and plate wells via pretreatment with human serum albumin increases the 
recovery of Aβ oligomers [101]. CSF samples from one Alzheimer’s patient (Discovery Life 
Sciences, USA) were thawed, transferred to microtiter plates that were either coated with 2% 
human serum albumin (HSA, isotonic with CSF) or left uncoated. The samples were then loaded 
onto 4 replicate gel lanes (lanes 6-9, albumin coated; lanes 1-4, uncoated; left most lane contains 
molecular weight standards [Precision Plus dual color standard, Bio-Rad Catalog #1610374]) 
and band intensity across the full length of the blot (loading lane to dye front) was quantified 
using the Alpha Innotech image system and Alpha View software (ProteinSimple, San Jose, 
CA).  Compared to patient samples from unblocked wells, coating microtiter plates with HSA 
increased recovery of Aβ oligomers (high molecular weight (>100kD) 36% increase, low 
molecular weight (<100 kD) 37% increase). (C-D) Primary antibody, 82E1, specifically detects 
Aβ oligomers with a range of molecular weights.  Alzheimer’s patient CSF samples (Discovery 
Life Sciences) were loaded 1:1 with native sample buffer (Bio-Rad Laboratories, Hercules, 
California, USA; catalogue #1610738); each of these lanes contains a CSF sample from a 
different patient (left most lane contains molecular weight standards). Lane 18 (both blots) 
contains pooled Alzheimer’s patient samples in which Aβ was depleted by a preincubation with 
4G8 antibody prior to loading on gel. Blots were probed with (left) or without (right) 82E1 
primary antibody (IBL America, Catalogue #10323) followed by Goat anti mouse IgG (H+L) 
HRP secondary antibody at 1:100,000 (10ng/ml, Millipore Catalog #AP308P), and band 
intensity across the full length of the blot (loading lane to dye front) was quantified. Aβ depleted 
patient samples (lane 18, left blot) have undetectable lower molecular weight species (size range 
24-150kDa); upper molecular weight banding (>150kDa) is obscured by the large IgG signal. In 
the absence of 82E1 primary antibody (lane 18, right blot) lower banding (24-150kDa) is 
undetectable above background (100% lower in average intensity) and higher molecular weight 
species (>150kDa) are 87% lower in average intensity. (E-F) The sensitivity of this method for 
detecting Aβ oligomers in CSF is 2ng/mL (LLOQ, CV<20%). The Cys-2 dimer standard was 
diluted two-fold in AD patient CSF (32.7 ng/mL to 2.04 ng/mL, source: University of 
Gothenburg) and loaded in 3 replicate groups on the same gel (E). The left and right most lanes 
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contain molecular weight standards. Quantification of Aβ protein intensity (F) across the full 
molecular weight range (top of gel to dye front) reveals a lower limit of quantification (defined 
as 5x above background) of 2ng/mL (CV<20%). Two Cys-2 dimer concentrations in the middle 
of this sensitivity range (10 and 20 ng/mL, vertical dashed lines in E) were included as standards 
on each gel measuring patient samples. This method is sufficient for detecting relative changes in 







Supplementary Fig. 5. Western blot of Aβ oligomers in CSF of AD patients treated with 
CT1812 in clinical trial COG0102. (A) Aβ oligomer concentrations in CSF samples from AD 
patients in a 28 day phase 1b/2a clinical trial of CT1812 vs. placebo were measured via gel 
electrophoresis using non-denaturing conditions. Samples were run on Tris-HCl gels, transferred 
to nitrocellulose and probed with 82E1 mouse monoclonal Aβ antibody (IBL America, 
Minneapolis, MN) and visualized by chemiluminescence. Total intensity of the entire length of 
each lane was quantified using an Alpha Innotech image system. This composite image 
represents 12 of the 13 patients that were measured and analyzed to produce the results found in 
Figure 5A. (B-G) Mean change from baseline of targeted AD CSF biomarkers. None of the 








Supplementary Figure 6. Pathway analysis of synaptic proteins significantly altered in CSF 
of CT1812-treated patients vs. placebo. (A) To understand the subset of synaptic biology 
specifically impacted by CT1812 treatment, we performed pathway analysis (nervous system 
focused) with IPA comparing synaptic proteins that were significantly different between CT1812 
and placebo patients (Fig 5 E, p < 0.05) to a Reference Set. The Reference Set was defined as the 
synaptic proteome specified in Lleó, et al, [102], further restricted to only the proteins detectable 
in the present COG0102 study CSF samples. The highest scoring Network was “Cell 
Morphology, Cellular Assembly and Organization, Cellular Development.” Within this network, 
14 out of 25 of the synaptic proteins were found, a number of proteins present that was a 
significantly greater than would be expected by random chance (IPA Score=26; p < 1x10-25). 
Levels of proteins shaded red were higher, whereas those shaded in green were lower in CSF 
from CT1812 (pooled) than placebo. (B) The top functions from this network include dendritic 
branching, cytoskeletal remodeling, and neurotransmission.   
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Supplementary Fig. 7. Inter-relationship of pTau sites in AD CSF from patients treated 
with CT1812. The change from baseline of each pTau site (in AD CSF) with all pTau sites was 
computed for all matched paired samples treated with drug (N=11) and Pearson correlation 
analysis was performed. (A) For visualization, a heatmap was generated using Pearson 
hierarchical clustering (Average Linkage, both rows and columns;  
https://software.broadinstitute.org/morpheus/). The color scale is a gradient reflecting the extent 
of association, with the highest positive correlation of 1 in dark red and highest negative 
correlation of -1 in dark blue. (B) Correlation coefficients and p-values for the 21 coregulated 
pairs of T-tau residues are shown. These results suggest that CT1812 may act upstream of tau 
kinases and phosphatases to impact tau phosphorylation at specific amino acid sites. 
 
 
 
